MV Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

MV Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.71K	Buy	22 +5	+29%	+$742	﹤0.01%	700
2026 Q1	$2.24K	Hold	17	–	–	﹤0.01%	737
2025 Q4	$2.41K	Hold	17	–	–	﹤0.01%	700
2025 Q3	$2.39K	Hold	17	–	–	﹤0.01%	691
2025 Q2	$2.14K	Buy	17 +5	+42%	+$573	﹤0.01%	700
2025 Q1	$1.33K	Sell	12 -4	-25%	-$507	﹤0.01%	730
2024 Q4	$2.18K	Buy	16 +6	+60%	+$742	﹤0.01%	685
2024 Q3	$1.15K	Buy	+10	New	+$1.37K	﹤0.01%	735

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MV Capital Management's NBIX Position: Q2 2026 in Review

MV Capital Management increased its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, buying an estimated $742 and bringing the position to 22 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #700.

MV Capital Management first reported a position in NBIX in Q3 2024 and has held it in 8 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

MV Capital Management held 22 shares of Neurocrine Biosciences worth $3.71K as of Q2 2026.
MV Capital Management bought 5 Neurocrine Biosciences shares in Q2 2026, an estimated $742.
Neurocrine Biosciences made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #700 holding.
MV Capital Management first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 8 quarters since.
780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.